WallStSmart
BNGO

Bionano Genomics Inc

NASDAQ: BNGO · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$1.27
-7.14% today

Updated 2026-06-05

Market cap
$14.46M
P/E ratio
P/S ratio
0.50x
EPS (TTM)
$-4.46
Dividend yield
52W range
$1 – $6
Volume
0.2M

Bionano Genomics Inc (BNGO) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2016201720182019202020212022202320242025
Operating cash flow$-23.50M$-20.82M$-19.94M$-29.53M$-38.31M$-71.93M$-124.82M$-125.18M$-68.92M$-16.34M
Capital expenditures$1.35M$1.02M$331716.00$61056.00$4.66M$1.46M$3.30M$1.69M$103000.00$0.00
Depreciation$1.12M$1.50M$1.32M$1.13M$1.48M$3.37M$9.84M$13.91M$14.23M
Stock-based comp$130643.00$382830.00$1.31M$1.35M$1.55M$9.72M$22.42M$15.18M$9.74M$4.53M
Free cash flow$-24.85M$-21.84M$-20.28M$-29.59M$-42.97M$-73.39M$-128.12M$-126.87M$-69.03M$-16.34M
Investing cash flow$-1.35M$-1.02M$-331716.00$-61056.00$-2.45M$-278.06M$82.77M$24.16M$73.84M
Financing cash flow$25.43M$17.61M$35.78M$30.38M$61.90M$336.11M$23.01M$113.81M$-13.69M
Dividends paid$2.00M
Share repurchases
Debt repayment
Net change in cash$15.50M$788644.00$21.14M$-13.88M$-19.04M

Frequently asked questions

What is Bionano Genomics Inc's revenue?

Bionano Genomics Inc's trailing twelve-month revenue is $28.74M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is BNGO?

In its most recent fiscal year, BNGO ran a gross margin of 21.95%, an operating margin of -116.95%, and a net margin of -92.59%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does BNGO generate?

BNGO produced $-16.34M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is BNGO's balance sheet healthy?

BNGO holds $2.99M in cash and equivalents against — in long-term debt, on $44.42M of shareholder equity. That debt is best read against the cash flow the business throws off each year.